Phio Pharmaceuticals Corp. Common Stock (PHIO) Stock Price

PHIOStock

$0.87−58.91%52W

Market Cap$10.12M

P/E—

PEG Ratio—

Div yield—

Beta0.91

PHIO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-42.38%

Price vs S&P 500 (4W)-12.43%

VGM Score43.97

Book Value / Share (Quarterly)$1.08

P/TBV (Annual)0.21x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.05

Price vs S&P 500 (YTD)-28.96%

Net Profit Margin (TTM)-3935.71%

EPS (TTM)$-1.39

10-Day Avg Trading Volume0.10M

EPS Excl Extra (TTM)$-1.39

EPS (Annual)$-9.05

ROI (Annual)-151.39%

Net Profit Margin (5Y Avg)-38214.76%

Cash / Share (Quarterly)$1.12

ROA (Last FY)-124.61%

EBITD / Share (TTM)$-1.42

ROE (5Y Avg)-105.54%

Operating Margin (TTM)-3957.14%

Cash Flow / Share (Annual)$-0.69

P/B Ratio0.80x

P/B Ratio (Quarterly)0.94x

Net Income / Employee (Annual)$-1,191,700

EV / Revenue (TTM)-20.54x

Net Interest Coverage (TTM)-1328.00x

ROA (TTM)-79.76%

EPS Incl Extra (Annual)$-9.05

Current Ratio (Annual)16.03x

Quick Ratio (Quarterly)7.62x

3-Month Avg Trading Volume0.47M

52-Week Price Return-58.91%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$3.13

P/S Ratio (Annual)505.99x

Asset Turnover (Annual)0.00x

52-Week High$4.19

Operating Margin (5Y Avg)-39948.09%

EPS Excl Extra (Annual)$-9.05

CapEx CAGR (5Y)-9.71%

Tangible BV CAGR (5Y)42.68%

26-Week Price Return-32.47%

Quick Ratio (Annual)15.69x

13-Week Price Return-15.43%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.39x

Enterprise Value$-2.88M

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-42.30%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-44550.00%

Cash / Share (Annual)$1.81

3-Month Return Std Dev45.91%

Net Income / Employee (TTM)$-2,150,700

ROE (Last FY)-151.39%

EPS Basic Excl Extra (Annual)$-9.05

Receivables Turnover (TTM)0.33x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.39

ROI (TTM)-87.41%

P/S Ratio (TTM)72.28x

Pretax Margin (5Y Avg)-39834.76%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$9.52

Price vs S&P 500 (52W)-74.44%

Year-to-Date Return-17.04%

5-Day Price Return-5.52%

EPS Normalized (Annual)$-9.05

ROA (5Y Avg)-88.07%

Net Profit Margin (Annual)-44550.00%

Month-to-Date Return-15.43%

Cash Flow / Share (TTM)$-7.19

EBITD / Share (Annual)$-9.35

Operating Margin (Annual)-44950.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-105.31%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.39

P/TBV (Quarterly)0.32x

P/B Ratio (Annual)0.56x

Pretax Margin (TTM)-3935.71%

Book Value / Share (Annual)$1.73

Price vs S&P 500 (13W)-18.11%

Beta0.91x

Revenue / Share (TTM)$0.00

ROE (TTM)-87.41%

52-Week Low$0.81

mGradeC

vgmGradeC

PHIO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.36	-$0.36	+0.00%(+$0.00)
Q1 2026	May 7, 2026	-$0.23	-$0.34	-44.68%(-$0.11)
Q4 2025	Mar 5, 2026	-$0.47	-$0.15	+68.09%(+$0.32)
Q3 2025	Nov 13, 2025	-$0.44	-$0.44	+0.00%(+$0.00)
Q2 2025	Aug 14, 2025	-$0.36	-$0.45	-25.00%(-$0.09)

PHIO Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.14

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PHIOPhio Pharmaceuticals Corp. Common Stock	—	—	C	72.3x	—	—	—	$0.87
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Phio Pharmaceuticals Corp. Common Stock

Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer immunotherapies using its proprietary INTASYL RNA gene silencing technology to enhance immune cells' ability to kill tumor cells. The platform precisely targets proteins that suppress anti-cancer immunity without requiring specialized drug delivery systems. The company's pipeline includes candidates PH-762 and PH-894, with all operations based in the United States.

PHIO Insider Transactions

BuySep 29, 2026
PLOTT RONALD TODD
Director
Shares: 10,000Value: $10,350
BuySep 22, 2026
BITTERMAN ROBERT J
Chief Executive Officer
Shares: 2,000Value: $2,058
BuySep 15, 2026
BRADFORD PATRICIA A
Director
Shares: 12,000Value: $12,360
BuyAug 19, 2026
PLOTT RONALD TODD
Director
Shares: 15,000Value: $17,100
BuyAug 18, 2026
BITTERMAN ROBERT J
Chief Executive Officer
Shares: 10,000Value: $10,600

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

PLURPluri Inc. Common StockBiological Products
PASGPassage Bio, Inc. Common StockBiological Products
INABIN8bio, Inc. Common StockBiological Products
INTSIntensity Therapeutics, Inc. Common stockBiological Products
BNKKBonk, Inc. Common StockCosmetics & Toiletries
BONBon Natural Life Limited Class A Ordinary SharesPharmaceutical Preparations
TANHTantech Holdings Ltd. Class A Common SharesIndustrial Chemicals
BMRABIOMERICA INCIn Vitro Diagnostics

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$0.81

High$4.19